NZ566399A - Use of tiotropium salts in the treatment of severe persistant asthma - Google Patents

Use of tiotropium salts in the treatment of severe persistant asthma

Info

Publication number
NZ566399A
NZ566399A NZ566399A NZ56639906A NZ566399A NZ 566399 A NZ566399 A NZ 566399A NZ 566399 A NZ566399 A NZ 566399A NZ 56639906 A NZ56639906 A NZ 56639906A NZ 566399 A NZ566399 A NZ 566399A
Authority
NZ
New Zealand
Prior art keywords
treatment
tiotropium
asthma
examples
medicament
Prior art date
Application number
NZ566399A
Other languages
English (en)
Inventor
Michael Engel
Stefan Heinrichs
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ566399(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ566399A publication Critical patent/NZ566399A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ566399A 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma NZ566399A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107266 2005-08-06
PCT/EP2006/064958 WO2007017438A1 (en) 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma

Publications (1)

Publication Number Publication Date
NZ566399A true NZ566399A (en) 2011-07-29

Family

ID=35432680

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ566399A NZ566399A (en) 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma

Country Status (16)

Country Link
US (3) US20070032516A1 (enExample)
EP (1) EP1915158A1 (enExample)
JP (1) JP2009504604A (enExample)
KR (1) KR20080039974A (enExample)
CN (1) CN101237872A (enExample)
AR (1) AR055597A1 (enExample)
AU (1) AU2006277968A1 (enExample)
BR (1) BRPI0614394A2 (enExample)
CA (1) CA2617717C (enExample)
IL (1) IL189248A0 (enExample)
MX (1) MX2008001506A (enExample)
NZ (1) NZ566399A (enExample)
RU (1) RU2422144C2 (enExample)
TW (1) TWI409072B (enExample)
WO (1) WO2007017438A1 (enExample)
ZA (1) ZA200800186B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
WO2007077162A1 (en) * 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma
MX2012005711A (es) * 2009-11-17 2012-10-05 Cipla Ltd Soluciones de inhalacion.
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5888396A (en) * 1996-12-17 1999-03-30 Perriello; Felix Anthony Bioremediation of pollutants with butane-utilizing bacteria
US6156503A (en) * 1997-03-03 2000-12-05 The Regents Of The University Of California Diagnosing asthma patients predisposed to adverse β-agonist reactions
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
CA2425539C (en) * 2000-10-12 2007-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
DE10216036A1 (de) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
WO2004014293A2 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
AU2006244683A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
AU2006248189A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
WO2007077162A1 (en) 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma

Also Published As

Publication number Publication date
CA2617717C (en) 2014-02-11
RU2422144C2 (ru) 2011-06-27
TW200744606A (en) 2007-12-16
US20130245059A1 (en) 2013-09-19
WO2007017438A1 (en) 2007-02-15
CA2617717A1 (en) 2007-02-15
RU2008108302A (ru) 2009-09-20
EP1915158A1 (en) 2008-04-30
ZA200800186B (en) 2009-04-29
IL189248A0 (en) 2008-08-07
KR20080039974A (ko) 2008-05-07
US20070032516A1 (en) 2007-02-08
AU2006277968A1 (en) 2007-02-15
MX2008001506A (es) 2008-04-07
BRPI0614394A2 (pt) 2011-03-29
AR055597A1 (es) 2007-08-29
TWI409072B (zh) 2013-09-21
JP2009504604A (ja) 2009-02-05
US20090163531A1 (en) 2009-06-25
CN101237872A (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
US20090088408A1 (en) Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
US20030018019A1 (en) Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
CA2495454C (en) Pharmaceutical compositions for inhalation containing a new anticholinergic in conjunction with corticosteroids and betamimetics
CA2534132C (en) Medicaments for inhalation comprising betamimetics and an anticholinergic
US20050026948A1 (en) Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20150224090A1 (en) Use of tiotropium salts in the treatment of moderate persistent asthma
US20130245059A1 (en) Use of Tiotropium Salts in the Treatment of Severe Persistent Asthma
US20060034776A1 (en) Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics
AU2012258410B2 (en) Use of tiotropium salts in the treatment of severe persistant asthma
MX2008007568A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
US20070072891A1 (en) Method for the Protection Against the Risk of Cardiac Disorders Comprising Administration of Tiotropium Salts
HK1126974A (en) Use of tiotropium salts in the treatment of moderate persistent asthma

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 AUG 2016 BY DENNEMEYER + CO

Effective date: 20130725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2017 BY DENNEMEYER + CO.

Effective date: 20160722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2018 BY DENNEMEYER + CO

Effective date: 20170726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2019 BY DENNEMEYER + CO

Effective date: 20180802

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2020 BY DENNEMEYER + CO.

Effective date: 20190719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2021 BY DENNEMEYER+CO.

Effective date: 20200720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2022 BY DENNEMEYER + CO.

Effective date: 20210726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2023 BY DENNEMEYER + CO. SARL.

Effective date: 20220725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2024 BY DENNEMEYER + CO. SARL

Effective date: 20230724

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2025 BY DENNEMEYER AND CO. SARL

Effective date: 20240722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2026 BY DENNEMEYER ET CO

Effective date: 20250724